CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
Alprazolam 2mg (2ALP/PLC) +5 moredrug
Likely dose
Alprazolam 2mg (2ALP/PLC)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03297944
NCT03297944Phase 4Completed

Alprazolam and Simulated Driving Performance: Next Day Effects

Marion Coe·interventional·Posted Sep 29, 2017·Updated Jan 29, 2020

In Brief

A Phase 4 clinical trial evaluating Alprazolam 2mg (2ALP/PLC), Alprazolam 1mg (1ALP/PLC), and 4 other interventions for Psychomotor Impairment. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This study evaluates the effect of anxiety drugs taken at night on the ability to drive a car the next day. Participants will receive alprazolam, placebo, or zolpidem at night before bed or in the morning before using a driving simulator to assess impairment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedSep 29, 2017
Enrollment StartSep 15, 2017
Primary CompletionOct 25, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.8 years ago

Interventions

Alprazolam 2mg (2ALP/PLC)drug

2mg alprazolam administered at night, placebo administered in the morning.

Alprazolam 1mg (1ALP/PLC)drug

1mg alprazolam administered at night, placebo administered in the morning.

Alprazolam 0.5mg (0.5ALP/PLC)drug

0.5mg alprazolam administered at night, placebo administered in the morning.

Zolpidem 10mg (ZOL/PLC)drug

10mg alprazolam administered at night, placebo administered in the morning.

Placebo (PLC/PLC)drug

Placebo administered at night, placebo administered in the morning.

Alprazolam 1mg (PLC/ALC)drug

Placebo administered at night, 1mg alprazolam administered in the morning.